|
Elizabeth M. Greetham age 57 has served as a director since November 2003. She presently serves as Chief Executive Officer and President of ACCL Financial Consultants Ltd. From 1998 until 2004 she served as a director of DrugAbuse Sciences Inc. and served as its Chief Executive Officer from August 2000 until 2004 and as Chief Financial Officer and Senior Vice President Business Development from April 1999 to August 2000. Prior to joining DrugAbuse Sciences Inc. Ms. Greetham was a portfolio manager with Weiss Peck & Greer an institutional investment management firm where she managed the WPG Life Sciences Funds L.P. which invests in select biotechnology stocks. She was previously a consultant to F. Eberstadt & Co. In total Ms. Greetham has over 25 years of experience as a portfolio manager and health care analyst in the United States and Europe. She is a member of the boards of directors of Nventa Biopharmaceuticals Corporation and Ligand Pharmaceuticals Inc. each a publicly-held corporation. Ms. Greetham earned a Master of Arts (Honours) degree in Economics from the University of Edinburgh Scotland in 1971. | 